Meg Dodge

Ms. Dodge is Head of Investor Relations and Corporate Communications at Rocket Pharma, a rare and devastating disease company seeking gene therapy cures. Previously, Ms. Dodge led Investor Relations and Communications at Krystal Biotech which received and launched the first-ever FDA-approved redosable gene therapy for a rare and life-threatening dermatological disease. Prior to her efforts in rare disease, Ms. Dodge led corporate strategy and development for two private biotechnology companies. Ms. Dodge began her career at Goldman Sachs, serving a number of roles before transitioning into the biotech industry. She holds a bachelor’s degree from Colby College, a J.D. from Syracuse University College of Law and an LLM from New York University Law School.